Martina Dören, M.D., a Alexander Rübig, M.D., b Herjan J. T. Coelingh Bennink, M.D., c and Wolfgang Holzgreve, M.D. d
|
|
- Rachel Watson
- 5 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY VOL. 75, NO. 3, MARCH 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy Martina Dören, M.D., a Alexander Rübig, M.D., b Herjan J. T. Coelingh Bennink, M.D., c and Wolfgang Holzgreve, M.D. d Department of Obstetrics and Gynecology, Westfälische Wilhelms-Universität, Münster, Münster, Germany Received June 16, 2000; revised and accepted November 7, Supported by NV Organon, Oss, The Netherlands. Reprint requests: Martina Dören, M.D, Free University of Berlin, Benjamin Franklin University Hospital, Clinical Research Center for Women s Health, Klingsorstrasse 109a, D Berlin, Germany (FAX: ; doeren@ukbf.fuberlin.de). a Free University of Berlin, Benjamin Franklin University Hospital, Clinical Research Center for Women s Health, Berlin, Germany. b University of Oviedo, Faculty of Obstetrics and Gynecology, Celestino Villamil, Oviedo, Spain. c Akzo Nobel NV Organon, Oss, The Netherlands. d Department of Obstetrics and Gynecology, Kantonsspital Basel, Basel, Switzerland /01/$20.00 PII S (00) Objective: To determine serum parameters reflective of androgen status in postmenopausal women using two types of hormone replacement therapy (HRT). Design: Randomized, double-blind, prospective 1-year trial of two oral HRT regimens. Setting: University hospital, department of obstetrics and gynecology, menopause clinic. Patient(s): 100 postmenopausal women 45 years. Intervention(s): Daily use of the progestogen tibolone (2.5 mg; n 50) or continuous combined 17- estradiol (2 mg) and norethindrone acetate (E NA, 1 mg; n 50). Main Outcome Measure(s): Measurements of total testosterone (total T), dehydroepiandrosterone sulfate (DHEAS), androstenedione (A), FSH, and sex-hormone-binding globulin (SHBG), and calculations of free testosterone (free T). Assessment of changes from baseline within and between groups after 6 and 12 months. Result(s): We found significant differences (% changes) in the tibolone group compared to baseline within the groups after both 6 and 12 months, respectively. Levels of free T doubled, total T decreased slightly, and SHBG decreased by half; DHEAS increased by approximately 20%; and FSH decreased. In the E NA group, levels of free T, total T, androstenedione, and FSH all decreased, and SHBG increased. Pre-trial levels of DHEAS, A, and total T were significantly higher in the E NA group. Between groups throughout the study, the changes from baseline were significant due to the different extent of FSH reduction, and opposite changes of free T, SHBG, and DHEAS. Conclusion(s): Both regimens modify plasma androgens, DHEAS, and SHBG differently. Tibolone decreased the levels of SHBG, and substantially increased free T and to a lesser extent increased DHEAS; this may reflect a modification of adrenal androgen production. Continuous combined estradiol and norethindrone acetate HRT suppressed the peripheral plasma androgens mediated by increased levels of SHBG. (Fertil Steril 2001;75: by American Society for Reproductive Medicine.) Key Words: Androgens, DHEAS, androstenedione, testosterone, SHBG, tibolone, estradiol, and norethindrone acetate replacement therapy, hormone replacement therapy, adrenal function The clinical effects of various hormone replacement therapy (HRT) regimens and their impact on estradiol and gonadotropin levels are well characterized; however, much less is known about the changes of plasma androgens. The available data are both largely observational and inconsistent regarding dehydroepiandrosterone sulfate (DHEAS), androstenedione (A), and total testosterone (total T) in women using HRT (1). DHEAS has been discussed in conjunction with a wide variety of diseases and conditions, including breast and prostate cancer, cognition, mood, immune function, and cardiovascular disease (2 5). We report the results of one prespecified secondary objective, which addressed changes of androgen status within a randomized, double-blind, 1-year HRT trial. This study was designed to assess endometrial response. The oral HRT regimen consisted of tibolone (2.5 mg daily), or continuous combined estradiol 554
2 (2.5 mg) and norethindrone acetate (E NA, 1 mg daily). Tibolone is a 7 -methyl derivative of norethynodrel, a progestogen, which also exerts androgenic and weak estrogenic effects (6). Previous trials of the study regimens have suggested differential effects upon androgens (7, 8). Thus, we measured total T, A, DHEAS, sex-hormone-binding globulin (SHBG), and calculated free testosterone (free T) within a comparative trial. The impact of both regimens on these parameters has not been well characterized and previous data are inconsistent. Both regimens are in clinical use in European countries to treat menopausal symptoms and prevent bone loss without inducing regular withdrawal bleeding. MATERIAL AND METHODS Study Participants and Design The study was approved by the Ethics Committee of the University of Münster. We recruited 100 white women as has been described elsewhere (9). The study s main objective was to assess changes in endometrial thickness. Secondary study objectives were to measure uterine bleeding (9), the impedance to pelvic blood flow (examined via transvaginal color Doppler sonography), and levels of plasma lipids (10). Women who participated had to be 45 years with a natural menopause (last bleeding 1 year prior to enrollment). In cases of previous HRT, a wash-out phase of 2 weeks was mandatory. This short interval allowed for recruitment of symptomatic women who were seeking a new HRT treatment. The exclusion criteria were endometrial thickness greater than 5 mm (double-layer); unexplained uterine bleeding; any cardiovascular or cerebrovascular disease, (para)thyroid or adrenal disease, any chronic disease, thromboembolic disorders, uncorrected hypertension, untreated hypercholesteremia, history of liver or renal disease; any malignancy less than 10 years prior to enrollment, or any history or presence of hormone-dependent malignancy; chronic use of anticonvulsants, diuretics, corticosteroids, antibiotics, heparin, lipidlowering drugs; alcohol and drug abuse; smoking (more than 10 cigarettes a day); and use of investigational drugs less than 30 days prior to enrollment. Women were randomized to receive oral daily treatment with tibolone (2.5 mg; n 50; Livial, NV Organon, Oss, The Netherlands), or 17- -estradiol (2 mg) and norethindrone acetate (1 mg; n 50; Kliogest, Novo Nordisk A/S, Copenhagen, Denmark). They took one active drug together with a visually matching placebo (double-dummy method) in the evenings. Endocrine Parameters The fasting serum samples were assessed at baseline, after 6 months, and after 12 months by one laboratory blinded to the treatment protocol (Bioscientia, Mainz, Germany). Samples were obtained between 0800 and 1400 hours, stored at 20 C, and processed within 72 hours. TABLE 1 Demographic characteristics. Tibolone (2.5 mg/day) (n 49) Estradiol (2 mg) norethisterone acetate (1 mg/day) (n 49) Age (year) (46 64) (46 69) Body mass index (kg/m 2 ) (16 35) (20 35) Menopausal age (year) (37 57) (38 57) Time since menopause (year) (1 20) (1 20) Pre-trial use of HRT (%) 57.1% 53.1% (n 28) (n 26) n n Estradiol (valerate) compounds CEE 4 4 Transdermal E 2 2 All data are mean values standard deviation, if not stated otherwise. Minimum and maximum values in brackets; OC oral contraceptives. Levels of estradiol (E), total T, DHEAS, and A were measured by radioimmunoassays (DPC-Biermann GmbH, Bad Nauheim, Germany; A: Bioscientia); the levels of FSH were measures by an immunoluminometric (Ciba-Corning, Fernwald, Germany); and the levels of SHBG were measured by an immunoradiometric assay (Orion Diagnostics, Espoo, Finland). To retain the double-blinded nature of the trial, E was only determined at baseline, as an increase (no change) was expected in the E NA (TIB) group, respectively, within the study period. The ranges of inter-assay coefficients of variations (CV) were 7% to 16.9% for E, 5.4% to 14.6% for total T, 6.4% to 9.5% for DHEAS, 6.3% to 9.2% for A, 4.4% to 6.7% for FSH, and 7.2% to 9.8% for SHBG. All intra-assay CVs were less than 10%. The lower limit of detection was 0.02 nmol/l for E, 0.7 nmol/l for total T, 0.3 mol/l for DHEAS, 0.69 nmol/l for A, 0.3 U/L for FSH, and 0.5 nmol/l for SHBG. Free T was calculated as the molar ratio of total T/SHBG (11). Statistics All analyses are based on Statistical Analyzing System version 6.08 or higher (SAS Institute, Cary, NC). Descriptive statistics include means standard deviation (SD), median, range, and absolute number(s) or percentage(s) where appropriate (Table 1). Baseline values, means SD, and medians of baseline endocrine parameters are plotted in Table 2. The P values of the two-sided Wilcoxon signed rank test on percent changes from baseline within and between groups are shown in Table 3. P values.05 (two-tailed) were regarded as statistically significant. FERTILITY & STERILITY 555
3 TABLE 2 Endocrine parameters baseline value. a Baseline Mean SD Tibolone Median Estradiol norethisterone acetate Baseline Mean SD Median Group comparison P b Estradiol (pmol/l) FSH (U/L) Total testosterone (nmol/l) Free testosterone (total testosterone/shbg) Androstendione (nmol/l) DHEAS ( mol/l) SHBG (nmol/l) a Intent-to-treat-groups; n 48 for each parameter in each group except estradiol in the tibolone group (n 47). b Wilcoxon rank-sum test of baseline values. Results The demographic data of the patients were similar (see Table 1); one patient in each group did not start HRT after randomization. Pre-trial use of HRT was 57.1% in the tibolone group and 53.1% in the E NA group; none of the women used injectables or implants. The duration of HRT use varied between 3 weeks and 8 years in the tibolone group, and 2 months and 9 years in the E NA group. Prior use of oral and transdermal HRT was very similar in both groups. Use of oral estrogen and progestogen regimens was predominant. Thirteen women did not complete the study. In the tibolone group, discontinuations were due to loss to follow-up examinations (n 2), and sleeplessness, facial acne, presence of an uterine fibroid, and apathy (n 1 each). In the TABLE 3 Endocrine parameters percent changes within and between groups. Tibolone Estradiol NETA Parameter Changes from baseline % changes Mean SD P a Mean SD P a Comparison P a FSH (U/L) Month (n 44) (n 43) Month (n 42) (n 41) Total T (nmol/l) Month (n 44) (n 43) Month (n 42) (n 41) Free T (total T/SHBG) Month (n 44) (n 43) Month (n 42) (n 41) A (nmol/l) Month (n 44) (n 43) Month (n 42) (n 41) DHEAS ( mol/l) Month (n 44).0098 } (n 43) Month (n 42) (n 41) SHBG (nmol/l) Month (n 44) (n 43) Month (n 42) (n 41) a Two-sided Wilcoxon signed rank tests on % changes from baseline within and between groups, respectively. 556 Dören et al. HRT and androgen status Vol. 75, No. 3, March 2001
4 FIGURE 1 Changes of DHEAS and SHBG from baseline: percent within 1 year, tibolone group. FIGURE 2 Changes of DHEAS and SHBG from baseline: percent within 1 year, estradiol and norethindrone acetate group. E NA group, terminations were due to uterine bleeding/ spotting (n 3), and fear of thrombosis, flatulence, depression, and weight increase (n 1 each). Compliance according to diaries and drug accountability was, on average, 98.1% in the tibolone and 97.3% in the E NA group. None of the participants presented with clinical signs of hirsutism. The pre-trial levels of DHEAS, A, and total T were significantly different between groups. There was a trend toward lower free T and E levels in the tibolone group (see Table 2). Within both groups, there were significant changes after 6 and 12 months for the levels of FSH, SHBG, and free and total T. Levels of FSH decreased to a greater extent in the E NA group. We measured changes of SHBG levels in opposite directions: a decrease in the tibolone group and an increase in the E NA group. Free T increased significantly it actually doubled (decreased) in the tibolone (E NA) group. Total T levels decreased in both groups, to a relatively larger extent in the E NA group. Within groups after 6 and 12 months, changes of both DHEAS and A were significant for one group only. The DHEAS levels increased in the tibolone group; the decline in the E NA group was significant only after 6 months. The suppression of A was significant in the E NA group; in the tibolone group there was a trend toward lower levels after 12 months (see Table 3). Differences between regimens after 6 and 12 months were significant for FSH, free T, SHBG, and DHEAS. The differences in the extent of suppression of total T and A by both regimens were significant only after 6 months (see Table 3; Figs. 1 and 2 ). DISCUSSION We found several distinctly different changes in the levels of plasma androgens, DHEAS, SHBG, and FSH in both extent and direction, depending on the type of HRT. There is only one 2-year uncontrolled study that has also suggested an increase of DHEAS levels with tibolone treatment in a small group of younger, early postmenopausal women (12). In controlled 2-year-studies, SHBG levels have decreased by 37% to 70% after 1 year (7, 13) and 55% after 2 years (7). Both the decrease of SHBG and FSH levels in our tibolone group are consistent with these trial results. Free T levels doubled in the tibolone group, most likely due to the suppression of SHGB. Previous controlled trials with the same continuous combined HRT did not show changes in the levels of DHEAS, androstenedione, and calculated free T, but did show suppression of SHBG within 2 years (8). One small 1-year study did not suggest any changes for levels of SHBG, total T, and free T (14). Overall, the findings are inconsistent, because SHBG levels increased in our E NA group and both A and total T decreased. Continuous use of NA in conjunction with E may have attenuated an otherwise larger rise of SHBG, compared with its sequential use as reported previously (8). A decrease of SHBG levels with HRT, allowing for higher levels of bioavailable steroids, is relevant for estrogen-dependent tissues. Whether concurrent changes in insulin resistance may be involved is unknown, and was beyond the scope of this trial. There are no long-term data available for the study regimens that address this issue. Tibolone did FERTILITY & STERILITY 557
5 not negatively influence glucose metabolism (15), as had been suggested by a small uncontrolled 3-month study. On the contrary, 3 months of continuous combined E NA decreased insulin sensitivity (16). Oral E (2 mg daily) may increase insulin sensitivity, but sequential oral E may reverse this effect, as suggested in an uncontrolled 1-year study (17). Thus, it is possible that long-term continuous combined E NA may decrease insulin sensitivity. DHEAS synthesis in women occurs exclusively in the adrenal cortex. In the postmenopause period, estrogen synthesis is completely dependent on peripheral conversion of the adrenal precursor steroids DHEAS, dehydroepiandrosterone (DHEA), and A. DHEA and its sulfate are also essentially involved in the synthesis of androgens in peripheral tissues (18). It is unknown whether HRT interferes with adrenal androgen synthesis and the subsequent peripheral metabolism in postmenopausal women. The hypotheses to explain the differences of HRT-associated changes in DHEAS levels the majority of which were generated from studies with conjugated equine estrogens include the enhancement of both 3 -hydroxysteroid dehydrogenase (3 - HSD) and 17,20-desmolase (19), a dissociation of these two enzyme activities (20), changes in the peripheral hydroxylation (21), and hepatic sulfation of DHEA (22). It is also unknown whether the increase of DHEAS by tibolone, which was also observed after stimulation of ovulation with menotropins (23) or use of danazol (24), could be the result of a specific enhancement of androgen-producing adrenal cells or whether it interferes with the endogenous stimulation by ACTH, which is known to increase DHEAS production. Exogenous E increased the production of DHEAS in one human adrenocortical tumor cell line (25). However, one recent study did not suggest any changes of adrenal enzyme activity, which was assessed by an adrenocorticotropin-hormone-stimulation test before and after use of transdermal E (26). Given that the plasma pool of DHEAS is several hundred times higher compared with testosterone in women, and that DHEAS is mainly bound to albumin not SHBG (5), the increase of DHEAS in the tibolone group by 20% within 1 year appears to be remarkable. Several limitations affect the interpretations of our results. There were significant differences in the baseline levels of DHEAS, A, and total T between the groups. However, statistical analyses controlled for these differences. Baseline DHEAS levels reflect the wide range of interindividual values (22). DHEAS is a specific individual marker, compared to other adrenal hormones such as cortisol (27). It is unknown whether any pre-trial HRT or the short wash-out period could have modified any of the measured parameters. Finally, the fraction of free T was calculated, not measured. In conclusion, both HRT regimens modified the levels of plasma androgens, DHEAS, and SHBG differently. The largest changes were found for the calculated fraction of free testosterone, which doubled in the tibolone group, likely due to a decrease of SHBG. The increase of DHEAS may reflect a modification of adrenal androgen production. Continuous combined E NA treatment suppressed peripheral plasma androgens, probably as a result of an increase in the level of SHBG. There was no apparent impact on DHEAS levels. Further trials should address the potential interference with adrenal steroidogenesis by various types of HRT and could delineate the physiological significance of any interaction. References 1. Tazuke S, Khaw KT, Barrett-Connor E. Exogenous estrogen and endogenous sex hormones. Medicine 1992;71: Casson PR, Hornsby PJ, Ghusn HF, Buster JE. Dehydroepiandrosterone (DHEA) replacement in postmenopausal women: present status and future promise. Menopause 1997;4: Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. Circulation 1995;91: Johannes CB, Stellato RK, Feldman HA, Longcope C, McKinlay JB. Relation of dehydrepiandrosterone and dehydrepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts women s health study. J Clin Epidemiol 1999; 52: Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39: Moore RA. Livial: a review of clinical studies. Br J Obstet Gynecol 1999;106(suppl 19): Milner M., Sinnott M., Gasparo D, Kelly A, Carole BK, Harrison R. Climacteric symptoms, gonadotropins, sex steroids, and binding proteins with conjugated equine estrogen-progestin and tibolone over two years. Menopause 1996;3: Obel EB, Munk-Jensen N, Svenstrup B, Bennett P, Micic S, Henrik- Nielsen R, et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993;16: Dören M, Rübig A, Coelingh Bennink HJT, Holzgreve W. Impact on uterine bleeding and endometrial thickness tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6: Dören M, Rübig A, Coelingh Bennink HJT, Holzgreve W. Resistance of pelvic arteries and plasma lipids in postmenopausal women: comparative study of tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Am J Obstet Gynecol 2000; 183: Carlström K, Gershagen R, Rannevik G. Free testosterone and testosterone/shbg index in hirsute women: a comparison of diagnostic accuracy. Gynecol Obstet Invest 1987;24: Erel CT, Elter K, Akman C, Ersavasti G, Altug A, Seyisoglu H, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998;69: Hänggi W, Lippuner K, Jäger P, Birkhäuser MH, Horber FF. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clin Endocrinol 1998;48: Raudaskoski T, Laatikainen T, Kauppila A. Sex-hormone binding globulin as an indicator of the hepatic impacts of continuous combined hormone replacement regimens. Maturitas 1998;29: Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 82: Kimmerle R, Heinemann L, Heise T, Bender R, Weyer C, Hischberger S, et al. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 1999;6: Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 2000;49: Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 1998;63: Lobo RA, Goebelsmann U, Brenner PF, Mishell DR Jr. The effects of estrogens on adrenal androgens in oophorectomized women. Am J Obstet Gynecol 1982;142: Liu CH, Laughlin GA, Fischer UG, Yen SSC. Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in post- 558 Dören et al. HRT and androgen status Vol. 75, No. 3, March 2001
6 menopausal women: evidence for a reduced 17,20-desmolase enzymatic activity. J Clin Endocrinol Metab 1990;71: Frye RF, Kroboth PD, Kroboth FJ, Stone RA, Folan M Salek FS, et al. Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adults. J Clin Pharmacol 2000;40: Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996;81: Haning RV, Austin CW, Carlson IH, Kuzma DL, Zweibel WJ. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis. Obstet Gynecol 1986;65: Murakami K, Nakagawa T, Yamashiro G, Araki K, Akasofu K. Adrenal steroids in serum during danazol therapy, taking into account crossreactions between danazol metabolites and serum androgens. Endocr J 1993;40: Gell JS, Oh J, Rainey WE, Carr BR. Effect of estradiol on DHEAS production in the human adrenocortical cell line, H295R. J Soc Gynecol Invest 1998;5: Slayden SM, Crabbe L, Bae S, Potter HD, Azziz R, Parker CR. The effect of 17 -estradiol on adrenocortical sensitivity, responsiveness, and steroidogenesis in postmenopausal women. J Clin Endocrinol Metab 1998;83: Thomas G, Frenoy N, Legrain S, Sebag-Lanoe R, Baulieu EE, Debuire B. Serum dehydroepiandrosterone sulfate levels as an individual marker. J Clin Endocrinol Metab 1994;9: FERTILITY & STERILITY 559
Issues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationDr Tarza Jamal Pharmacology Lecture 2
Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination
More informationCLINICAL ASSESSMENT AND DIAGNOSIS
FERTILITY AND STERILITY VOL. 77, NO. 4, SUPPL 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. CLINICAL ASSESSMENT
More informationInsight into male menopause'
Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone
More informationThe physiology of normal androgen production in
Mayo Clin Proc, April 2004, Vol 79 (Supplement) Formulations and Use of Androgens S3 Supplement Article Formulations and Use of Androgens in Women MICHELINE C. CHU, MD, AND ROGERIO A. LOBO, MD The physiology
More informationPros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery
Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery David T Zava, PhD ZRT laboratory A Guide to Steroid Hormone Testing in Different Body Fluids Following
More informationReproductive DHT Analyte Information
Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationNatural estrogens estradiol estrone estriol
Estrogens Natural estrogens estradiol estrone estriol Nonsteroidal synthetic Diethylstilbestrol Chlorotrianisene Methallenestril Steroidal synthetic Ethinyl estradiol Mestranol Quinestrol To decrease some
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationAlthough women produce only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Mary Lake Polan, MD, PhD, MPH Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Chair Emeritus,
More informationThe Science of. NUTRICULA Longevity Journal
32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationOriginal Research Declining testicular function in aging men
(2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related
More informationSkin metabolism of steroid hormones as endogenous compounds?
Skin metabolism of steroid hormones as endogenous compounds? Van Luu-The Department of Molecular Medicine Laval University Québec, Canada This work has been supported by L Oréal Research Steroid hormones
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More informationMonitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc.
Mr Mark Newman Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. 2 Avoiding Pitfalls in (B)HRT Monitoring and Picking the Right Lab Test Objectives: Outline how expected
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationFigure 2. RESULTS DATA ANALYSIS
ANDROGEN PARAMETERS IN HIRSUTE AND NORMAL FEMALE PATIENTS: IS THERE A ROLE FOR THE FREE ANDROGEN INDEX (FAI)? Castracane VD 1, Childress E 1, Tawwater B 1, Vankrieken L 2, El Shami AS 2 ( 1 Department
More informationCONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS
CONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS 13 Septembre 2018 Quebec, Canada 1 ENDOCEUTICS No. 1 Innovative pharmaceutical company in menopausal women s health in the world 2 Facilities Head
More informationUnderstanding combined oral contraception
Understanding combined oral contraception Paula Briggs, FFSRH Consultant in Community Sexual and Reproductive Health Southport and Ormskirk NHS Hospital Trust May Logan Centre, Bootle, L20 5DQ paulaeb@aol.com
More informationAssociate Professor Geoff Braatvedt
Associate Professor Geoff Braatvedt Endocrinologist Diabetologist and Physician Green Lane and Auckland City Hospitals Auckland 14:00-14:55 WS #145: Approach to Low Testosterone Values 15:05-16:00 WS #157:
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationPRODUCT INFORMATION PROVIRON
PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More informationAffirming Care of the Transgender Patient
Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute
More informationAndrogen Measurements
Chapter 5 / Androgen Measurements 63 Androgen Measurements Methods, Interpretation, and Limitations 5 Frank Z. Stanczyk SUMMARY Androgens are measured primarily in serum by direct and indirect (with one
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationNational Institute for Public Health and the Environment Annual CRL workshop 22 October Update on natural Hormone studies
2008 Annual CRL workshop 22 October 2008 Update on natural Hormone studies Natural hormone studies: update Possible approaches - C12/C13 ratio: can result in proof of abuse - Determination of intact esters
More informationX/97/$03.00/0 Vol. 82, No. 8 Journal of Clinical Endocrinology and Metabolism Copyright 1997 by The Endocrine Society
0021-972X/97/$03.00/0 Vol. 82, No. 8 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society Physiological Changes in Dehydroepiandrosterone Are Not Reflected
More informationJeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017
Jeremiah Murphy, MD Mercy Urology Clinic October 21, 2017 Describe an appropriate strategy for the evaluation and diagnosis of male hypogonadism Endocrine Society Clinical Practice Guideline-2010 Review
More informationsocial impairment. The following exclusion criteria applied: age under 18 years; weight under 45 kg or over 80 kg;
Postgrad Med J (1991) 67, 450-454 The Fellowship of Postgraduate Medicine, 1991 Low dose danazol in the treatment of the premenstrual syndrome Miriam Deeny, Robert Hawthorn and D. McKay Hart Division ofobstetrics
More informationTestosterone Use and Effects
Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).
More informationChapter 5. General discussion
Chapter 5. General discussion 127 Chapter 5 In 2003, two review papers concluded that endogenous androgens do not show any consistent association with cardiovascular disease (CVD) risk 1,2. Apparently,
More informationIcd 10 hormone replacement therapy male
Icd 10 hormone replacement therapy male 2018 ICD - 10 code for Hormone replacement therapy is Z79.890. Lookup the complete ICD 10 Code details for Z79.890. The ICD - 10 system requires that. TEENren who
More informationGonadal Hormones & Inhibitors
Gonadal Hormones & Inhibitors Estrogens Natural estrogens estradiol estrone estriol Nonsteroidal synthetic Diethylstilbestrol Chlorotrianisene Methallenestril Steroidal synthetic Ethinyl estradiol Mestranol
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationPackage Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)
Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains
More informationJOSEPH W. GOLDZIEHER, M,D.t C, BRANDON CHENAULT, M.D. ARMANDO DE LA PENA, M.S. TAZEWELL S. DOZIEIt DUANE C. KRAEMER, D.V.M., PH.D.
FERTILITY AND STERILITY Copyright,< 1978 The American Fertility Society Vol. 29, No.4, April 1978 Printed in U.SA. COMPARATIVE STUDIES OF THE ETHYNYL ESTROGENS USED IN ORAL CONTRACEPTIVES: EFFECTS WITH
More informationComplete. Male Hormones SAMPLE PATIENT. Patient: Order Number: Age: 47 Sex: M MRN:
Patient: Age: 47 Sex: M MRN: SAMPLE PATIENT Order Number: 81200334 Completed: September 20, 2007 Received: September 20, 2007 Collected: September 20, 2007 Complete Male Hormones Patient: SAMPLE PATIENT
More informationTestosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationLCMSMS Solutions For Steroid Analysis
LCMSMS Solutions For Steroid Analysis Dan Blake Manager, Clinical Applications For Research Use Only. Not for use in diagnostic procedures. RUO-MKT-18-1166-A Agenda Special considerations for steroid analysis
More informationTESTOFEN. Anabolic & Androgenic Activity GENCOR PACIFIC, INC. Fenugreek Extract standardized for FENUSIDE TM. Copyright 2005 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920E. Orangethorpe Avenue, Suite B, Anaheim, CA. 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com manu@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationRelationship between Aerobic Training and Testosterone Levels in Male Athletes
Relationship between Aerobic Training and Testosterone Levels in Male Athletes Siu Yuen Ng Biology 493 13 th December, 2010 Abstract Salivary testosterone levels of 11 athletes and 15 non athletes were
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationREPRODUCTIVE ENDOCRINOLOGY
FERTILITY AND STERILITY VOL. 79, NO. 1, JANUARY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. REPRODUCTIVE ENDOCRINOLOGY
More informationFree testosterone levels during danazol therapy*
FERTILITY AND STERILITY Copyright 1983 The American Fertility Society Printed in U.8A. Free testosterone levels during danazol therapy* Bo Nilsson, M.D. t:j: Ragnar Stidergard, Ph.D. Mats-GQran Damber,
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women s logo is placed throughout
More informationPRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl
PRODUCT INFORMATION SUSTANON '250' NAME OF THE MEDICINE Sustanon '250' ('250' mg/ml for injection): testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate.
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationSIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE
SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE Pages with reference to book, From 216 To 218 S.J. Khurshid, M. Riaz, S. Ahmed ( Nuclear Chemistry Division, Pakistan
More informationMaturitas 67 (2010) Contents lists available at ScienceDirect. Maturitas. journal homepage:
Maturitas 67 (2010) 39 45 Contents lists available at ScienceDirect Maturitas journal homepage: www.elsevier.com/locate/maturitas Review Androgen deficiency in women; role of accurate testosterone measurements
More informationSue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013
Sue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013 Agenda Value of WoE/MoA determinations in EDSP Information used to examine potential endocrine activity and/or
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25
More informationA Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan
ORIGINAL ARTICLE A Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan Ming-Huei Cheng 1,2, Bill Ken-Jen Yu 1 4, Sheng-Ping
More informationAre Steroids Worth the Risk?
Are Steroids Worth the Risk? Dominic has baseball on the brain. Just being good isn't enough he wants to be the best. He dreams of playing in the majors someday, but worries about the intense competition
More informationUse of Performance Enhancing Substances Good Chemistry Gone Bad. Evan M. Klass, M.D., F.A.C.P.
Use of Performance Enhancing Substances 2017 Good Chemistry Gone Bad Evan M. Klass, M.D., F.A.C.P. Doping the use of banned athletic performance-enhancing drugs by competitors Performance enhancing substances
More informationAntiduretic Hormone, Growth. Hormone & Anabolic Steroids
Goudarz Sadeghi, DVM, PhD, DSc Associate Professor of Pharmacology University of Tehran Faculty of Veterinary Medicine Veterinary Pharmacology Endocrine System Antiduretic Hormone, Growth Hormone & Anabolic
More informationFINCAR Tablets (Finasteride)
Published on: 10 Jul 2014 FINCAR Tablets (Finasteride) Composition FINCAR Tablets Each film-coated tablet contains: Finasteride USP - 5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of
More informationCHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY. Ms. K. GOWRI. M.Pharm., Lecturer.
CHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY Ms. K. GOWRI. M.Pharm., Lecturer. Muscle Cell Metabolism Muscle Cells Provide ATP to Drive the Crossbridge Cycle The sources of ATP: Available ATP in the
More informationWADA Technical Document TD2014EAAS. Endogenous Anabolic Androgenic Steroids Measurement and Reporting
Endogenous Anabolic Androgenic Steroids Measurement and Reporting 1.0 Introduction The purpose of this Technical is to harmonize the approaches to the measurement and reporting of endogenous anabolic androgenic
More informationThe safety of postmenopausal testosterone therapy
Review The safety of postmenopausal testosterone therapy Kate Maclaran 1,2 & Nick Panay* 1 Testosterone is increasingly used as part of postmenopausal HRT regimens. Unfortunately, few androgenic preparations
More informationInappropriate Testosterone Billings
Inappropriate Testosterone Billings Carla Patrick-Fagan March 30, 2015 Truven Health Analytics Inc. All Rights Reserved. 1 Agenda Proposed in the 2015 analytic plan Steroid prescriptions Code of Federal
More informationCHEMILUMINESCENCE ENZYME IMMUNOASSAY (CLIA) TESTOSTERONE. Testosterone. Cat #
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland Hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationEstrogens & androgens ا.م.د.اسامة ايوب lec:4-6
Estrogens & androgens ا.م.د.اسامة ايوب lec:4-6 Sex hormones produced by the gonads are necessary for conception embryonic maturation, and development of primary and secondary sexual characteristics at
More informationab Androstenedione ELISA Kit
ab108672 Androstenedione ELISA Kit Instructions for Use A competitive immunoenzymatic assay for the quantitative measurement of Androstenedione in serum and plasma (citrate). This product is for research
More informationControl of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy
British Journal of Dermatology (1986) 115, 269-274. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy R.S.SAWERS, VALERIE A.RANDALL* AND
More informationDUPROST Capsules (Dutasteride)
Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationPharmacotherapy of Metabolic Modulation in Acute Burns Mitchell J Daley, PharmD, FCCM, BCPS
Pharmacotherapy of Metabolic Modulation in Acute Burns Mitchell J Daley, PharmD, FCCM, BCPS Clinical Pharmacy Specialist, Critical Care Dell Seton Medical Center at the University of Texas and Seton Healthcare
More informationSex Hormones and Metabolites
Accession # 00268796 Male Sample Report 123 A Street Sometown, CA 90266 Sex Hormones and Metabolites Ordering Physician: Precision Analytical DOB: 1967-08-09 Age: 50 Gender: Male Last Menstrual Period:
More informationReproductive. Androgens Analytes Information
Reproductive Androgens Analytes Information - 1 - Androgens Introduction Androgens are a group of C 19 steroids. They are responsible for masculinization of the genital tract as well as the development
More information26-G Keewaydin Drive, Salem, NH P: (800) F: (603)
Dihydrotestosterone ELISA For the quantitative determination of DHT in serum. For Research Use Only. Not for Use in Diagnostic Procedures. Catalog Number: 11-DHTHU-E01 Size: 96 wells Version: 4.1 August
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationUpdates on Anti-doping and TUE Management in Paralympic Sport
International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops
More informationCastration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009
Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009 Charles J Ryan, MD Associate Professor of Clinical Medicine Helen Diller Family
More informationPhysician Copy. Patient: SAMPLE PATIENT DOB: Sex: MRN: ACH24.1
Physician Copy Patient: SAMPLE PATIENT DOB: Sex: MRN: ACH24.1 ID: Steroidogenic Pathway At-A-Glance 0.60 1 0.10 RR : 0-0.90 RR : 0.30-4.20 RR : 0.60-2.50 0.10 RR : 0.16-0.65 1.48 RR : 1.20-6.10 2.47 RR
More informationCHEMILUMINESCENCE IMMUNOASSAY (CLIA) Testosterone
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland Hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationMetabolism of DHEA in postmenopausal women following percutaneous administration
Journal of Steroid Biochemistry & Molecular Biology 103 (2007) 178 188 Metabolism of DHEA in postmenopausal women following percutaneous administration Fernand Labrie a,, Alain Bélanger a, Patrick Bélanger
More informationChapter 37 (pages ): Hereditary Angioedema and Bradykinin-Mediated Angioedema Prepared by: Sarah Spriet, DO
FIT Board Review Corner May 2017 Welcome to the FIT Board Review Corner, prepared by Tammy Peng, MD, and Amar Dixit, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the Board
More informationTreatment of androgen deficiency in the aging male
Treatment of androgen deficiency in the aging male The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Although guidelines for androgen replacement therapy for
More informationThat testosterone supplementation might improve some
GERIATRIC BIOSCIENCE Androgen Supplementation in Older Women: Too Much Hype, Not Enough Data Ma Clara M. Padero, MD, Shalender Bhasin, MD, and Theodore C. Friedman, MD, PhD Androgen supplementation in
More informationClinical Policy: Testosterone Reference Number: AZ.CP.PHAR.02 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.02 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Implantable Hormone Pellets Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...
More informationA mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men
European Journal of Endocrinology (2004) 151 241 249 ISSN 0804-4643 EXPERIMENTAL STUDY A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men Paul
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFormally known as anabolic steroids or anabolic-androgenic steroids, but they are sometimes called 'roids', 'gear' or 'juice'.
Steroids What are steroids? Steroids are drugs that help the growth and repair of muscle tissue. They are synthetic hormones that imitate male sex hormones, specifically testosterone. Steroids can increase
More informationMI Androgen Deficiency Hypogonadism
MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218
More informationANDROGENS PLAY AN essential role in the sexual
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information